SCHEMBL5619495

SCHEMBL5619495

COc1cc(Nc2nc(-c3ccc(NC(=O)CN)cc3)nn3c(C)nc(C)c23)cc(OC)c1OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
KMT2A Q03164 3/20 0.40
RXFP1 Q9HBX9 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
LMNA P02545 3/20 0.40
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39
TUBB3 Q13509 1/20 0.39
TUBB2A Q13885 1/20 0.39
TUBB8 Q3ZCM7 1/20 0.39
TUBA3E Q6PEY2 1/20 0.39
TUBA1A Q71U36 1/20 0.39
TUBA1C Q9BQE3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5621060 0.93 MAPT (0.45) MAPTKMT2ARXFP1MEN1LMNA
SCHEMBL5620937 0.93 MAPT (0.43) MAPTKMT2ARXFP1KDM4EMEN1
SCHEMBL5620338 0.92 MAPT (0.43) MAPTKMT2ARXFP1KDM4EMEN1
SCHEMBL8351472 0.90 SMN1; SMN2 (0.36) MAPTKMT2AKDM4EMEN1LMNA
SCHEMBL5619813 0.89 BRAF (0.50) MAPTKMT2ARXFP1KDM4EMEN1
SCHEMBL5619992 0.86 RAF1 (0.52) MAPTKMT2AHSD17B10LMNABRAF
SCHEMBL14525093 0.86 SUV39H2 (0.40) MAPTKMT2ARXFP1KDM4EMEN1
SCHEMBL5619503 0.85 PLK1 (0.46) MAPTKMT2AMEN1TUBB4ATUBB
SCHEMBL5621058 0.84 MAPT (0.41) MAPTRXFP1LMNABRAFPLK1
SCHEMBL6291417 0.84 PLK1 (0.45) MAPTKMT2AMEN1TUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202243-B2 Substituted imidazotriazines BAYER HEALTHCARE AG (DE) 2007-04-10 US disclosed
US-7202243-B2 Substituted imidazotriazines BAYER HEALTHCARE AG (DE) 2007-04-10 US disclosed
US-7202243-B2 Substituted imidazotriazines BAYER HEALTHCARE AG (DE) 2007-04-10 US disclosed
US-20060166993-A1 Substituted imidazotriazines BAYER HEALTHCARE AG (DE) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166993-A1 Substituted imidazotriazines SNCA, PARK7, TPMT MAPT 164/4885KMT2A 854/4885RXFP1 4786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.